Phase I/II Examination of Transurethral Ethanol Ablation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia

M. K. Plante, L. S. Marks, R. Anderson, Christopher Amling, D. Rukstalis, G. Badlani, L. Getlin, E. Vang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: We assessed the safety of transurethral ethanol ablation of the prostate as a treatment for men with symptomatic benign prostatic hyperplasia and determined the efficacy of this procedure. Materials and Methods: We performed a multicenter randomized trial on 79 men, 50 to 79 years old, who had drug refractory voiding symptoms (International Prostate Symptom Score greater than 12) and prostate volumes of 30 to 80 cc. Ethanol was injected transurethrally into the prostate with a curved cystoscopic needle in men randomly assigned to 1 of 3 doses: 15%, 25% or 40% of prostate volume by transrectal ultrasound. Followup evaluations were performed 1, 3 and 6 months later. Postoperative cystoscopy was performed on all patients to evaluate ablation extent and extraprostatic effects. Transrectal ultrasound volume determinations were obtained before and 6 months after transurethral ethanol ablation of the prostate. Results: Adverse events were generally mild or moderate, and included hematuria (42.9%), irritative voiding symptoms (40.3%), pain/discomfort (25.6%) and urinary retention (22.1%). No serious adverse events were reported. Statistically significant improvements were seen in International Prostate Symptom Score, quality of life, maximum flow rate and prostate volume reduction (p

Original languageEnglish (US)
Pages (from-to)1030-1035
Number of pages6
JournalJournal of Urology
Volume177
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Prostate
Ethanol
Therapeutics
Cystoscopy
Urinary Retention
Hematuria
Multicenter Studies
Needles
Quality of Life
Safety
Pain
Pharmaceutical Preparations

Keywords

  • ethanol
  • injections
  • prostatic hyperplasia
  • transurethral resection of prostate

ASJC Scopus subject areas

  • Urology

Cite this

Phase I/II Examination of Transurethral Ethanol Ablation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia. / Plante, M. K.; Marks, L. S.; Anderson, R.; Amling, Christopher; Rukstalis, D.; Badlani, G.; Getlin, L.; Vang, E.

In: Journal of Urology, Vol. 177, No. 3, 03.2007, p. 1030-1035.

Research output: Contribution to journalArticle

Plante, M. K. ; Marks, L. S. ; Anderson, R. ; Amling, Christopher ; Rukstalis, D. ; Badlani, G. ; Getlin, L. ; Vang, E. / Phase I/II Examination of Transurethral Ethanol Ablation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia. In: Journal of Urology. 2007 ; Vol. 177, No. 3. pp. 1030-1035.
@article{5090dbba838c453e9303c3b9ac6df1fe,
title = "Phase I/II Examination of Transurethral Ethanol Ablation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia",
abstract = "Purpose: We assessed the safety of transurethral ethanol ablation of the prostate as a treatment for men with symptomatic benign prostatic hyperplasia and determined the efficacy of this procedure. Materials and Methods: We performed a multicenter randomized trial on 79 men, 50 to 79 years old, who had drug refractory voiding symptoms (International Prostate Symptom Score greater than 12) and prostate volumes of 30 to 80 cc. Ethanol was injected transurethrally into the prostate with a curved cystoscopic needle in men randomly assigned to 1 of 3 doses: 15{\%}, 25{\%} or 40{\%} of prostate volume by transrectal ultrasound. Followup evaluations were performed 1, 3 and 6 months later. Postoperative cystoscopy was performed on all patients to evaluate ablation extent and extraprostatic effects. Transrectal ultrasound volume determinations were obtained before and 6 months after transurethral ethanol ablation of the prostate. Results: Adverse events were generally mild or moderate, and included hematuria (42.9{\%}), irritative voiding symptoms (40.3{\%}), pain/discomfort (25.6{\%}) and urinary retention (22.1{\%}). No serious adverse events were reported. Statistically significant improvements were seen in International Prostate Symptom Score, quality of life, maximum flow rate and prostate volume reduction (p",
keywords = "ethanol, injections, prostatic hyperplasia, transurethral resection of prostate",
author = "Plante, {M. K.} and Marks, {L. S.} and R. Anderson and Christopher Amling and D. Rukstalis and G. Badlani and L. Getlin and E. Vang",
year = "2007",
month = "3",
doi = "10.1016/j.juro.2006.10.024",
language = "English (US)",
volume = "177",
pages = "1030--1035",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Phase I/II Examination of Transurethral Ethanol Ablation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia

AU - Plante, M. K.

AU - Marks, L. S.

AU - Anderson, R.

AU - Amling, Christopher

AU - Rukstalis, D.

AU - Badlani, G.

AU - Getlin, L.

AU - Vang, E.

PY - 2007/3

Y1 - 2007/3

N2 - Purpose: We assessed the safety of transurethral ethanol ablation of the prostate as a treatment for men with symptomatic benign prostatic hyperplasia and determined the efficacy of this procedure. Materials and Methods: We performed a multicenter randomized trial on 79 men, 50 to 79 years old, who had drug refractory voiding symptoms (International Prostate Symptom Score greater than 12) and prostate volumes of 30 to 80 cc. Ethanol was injected transurethrally into the prostate with a curved cystoscopic needle in men randomly assigned to 1 of 3 doses: 15%, 25% or 40% of prostate volume by transrectal ultrasound. Followup evaluations were performed 1, 3 and 6 months later. Postoperative cystoscopy was performed on all patients to evaluate ablation extent and extraprostatic effects. Transrectal ultrasound volume determinations were obtained before and 6 months after transurethral ethanol ablation of the prostate. Results: Adverse events were generally mild or moderate, and included hematuria (42.9%), irritative voiding symptoms (40.3%), pain/discomfort (25.6%) and urinary retention (22.1%). No serious adverse events were reported. Statistically significant improvements were seen in International Prostate Symptom Score, quality of life, maximum flow rate and prostate volume reduction (p

AB - Purpose: We assessed the safety of transurethral ethanol ablation of the prostate as a treatment for men with symptomatic benign prostatic hyperplasia and determined the efficacy of this procedure. Materials and Methods: We performed a multicenter randomized trial on 79 men, 50 to 79 years old, who had drug refractory voiding symptoms (International Prostate Symptom Score greater than 12) and prostate volumes of 30 to 80 cc. Ethanol was injected transurethrally into the prostate with a curved cystoscopic needle in men randomly assigned to 1 of 3 doses: 15%, 25% or 40% of prostate volume by transrectal ultrasound. Followup evaluations were performed 1, 3 and 6 months later. Postoperative cystoscopy was performed on all patients to evaluate ablation extent and extraprostatic effects. Transrectal ultrasound volume determinations were obtained before and 6 months after transurethral ethanol ablation of the prostate. Results: Adverse events were generally mild or moderate, and included hematuria (42.9%), irritative voiding symptoms (40.3%), pain/discomfort (25.6%) and urinary retention (22.1%). No serious adverse events were reported. Statistically significant improvements were seen in International Prostate Symptom Score, quality of life, maximum flow rate and prostate volume reduction (p

KW - ethanol

KW - injections

KW - prostatic hyperplasia

KW - transurethral resection of prostate

UR - http://www.scopus.com/inward/record.url?scp=33846819033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846819033&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.10.024

DO - 10.1016/j.juro.2006.10.024

M3 - Article

C2 - 17296405

AN - SCOPUS:33846819033

VL - 177

SP - 1030

EP - 1035

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -